“4+7”药品招标的反思

Reflection on “4+7” Drug Bidding

我国采用药品招标方式降低药品价格,以解决“看病贵”难题。本文研究了中国近20年的招标模式,特别是1年来出现的“4+7”招标和“4+7扩围”招标的现状,以及医改10多年来医药卫生费用的支出情况。结果表明,降低药品价格并不能完全解决“看病贵”问题,并应警惕一些优质低价的药品从市场消失。政府应该对一些低价药品进行生产成本调研,对于接近或低于生产成本的药品,不宜纳入招标范围,而应直接挂网销售。同时,企业需考虑药品的实际综合成本,理智报价,确保产品质量,以满足临床用药安全、有效。

In order to solve the problem of“expensive medical treatment”,the Chinese government adopts drug bidding to reduce the drug prices.The bidding mode in China in the past 20 years was studied in this paper,especially the current situation of“4+7”bidding and“4+7 expansion”bidding in the past year,and the expenditure of medical and health expenses in the past ten years of medical reform.The results showed that reducing the price of drugs could not solve the problem of“expensive medical treatment”completely.It should be alert that some high-quality and low-cost drugs disappeared from the market.The government should investigate the production cost of some low-cost drugs.The drugs close to or lower than the production cost should not be included in the scope of bidding,but should be directly sold on the Internet.At the same time,enterprises should consider the actual comprehensive cost of drugs,make rational quotation,and ensure the product quality,so as to meet the clinical safety and effective drug use.